jamp-vardenafil tablet
jamp pharma corporation - vardenafil (vardenafil hydrochloride) - tablet - 10mg - vardenafil (vardenafil hydrochloride) 10mg - phosphodiesterase type 5 inhibitors
jamp-vardenafil tablet
jamp pharma corporation - vardenafil (vardenafil hydrochloride) - tablet - 20mg - vardenafil (vardenafil hydrochloride) 20mg - phosphodiesterase type 5 inhibitors
ag-vardenafil tablet
angita pharma inc. - vardenafil (vardenafil hydrochloride) - tablet - 5mg - vardenafil (vardenafil hydrochloride) 5mg - phosphodiesterase type 5 inhibitors
ag-vardenafil tablet
angita pharma inc. - vardenafil (vardenafil hydrochloride) - tablet - 10mg - vardenafil (vardenafil hydrochloride) 10mg - phosphodiesterase type 5 inhibitors
ag-vardenafil tablet
angita pharma inc. - vardenafil (vardenafil hydrochloride) - tablet - 20mg - vardenafil (vardenafil hydrochloride) 20mg - phosphodiesterase type 5 inhibitors
jamp-vardenafil odt tablet (orally disintegrating)
jamp pharma corporation - vardenafil (vardenafil hydrochloride trihydrate) - tablet (orally disintegrating) - 10mg - vardenafil (vardenafil hydrochloride trihydrate) 10mg - phosphodiesterase type 5 inhibitors
vardenafil krka 5mg film-coated tablets
krka, d.d., novo mesto - vardenafil hydrochloride trihydrate - film-coated tablet - 5 milligram(s) - drugs used in erectile dysfunction; vardenafil
vardenafil krka 10 mg film-coated tablets
krka, d.d., novo mesto - vardenafil hydrochloride trihydrate - film-coated tablet - 10 milligram(s) - drugs used in erectile dysfunction; vardenafil
vardenafil krka 20 mg film-coated tablets
krka, d.d., novo mesto - vardenafil hydrochloride trihydrate - film-coated tablet - 20 milligram(s) - drugs used in erectile dysfunction; vardenafil
vardenafil hydrochloride tablet
macleods pharmaceuticals limited - vardenafil (unii: uce6f4125h) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride tabletswith nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including v ardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of v ardenafil hydrochloride tabletsfor the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil hydrochloride tablets are not indicated for use in females. there are no data with the use of varde